It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The envelope (E) protein of flaviviruses is functionally associated with viral tissue tropism and pathogenicity. For yellow fever virus (YFV), viscerotropic disease primarily involving the liver is pathognomonic for wild-type (WT) infection. In contrast, the live-attenuated vaccine (LAV) strain 17D does not cause viscerotropic disease and reversion to virulence is associated with neurotropic disease. The relationship between structure-function of the E protein for WT strain Asibi and its LAV derivative 17D strain is poorly understood; however, changes to WT and vaccine epitopes have been associated with changes in virulence. Here, a panel of Asibi and 17D infectious clone mutants were generated with single-site mutations at the one membrane residue and each of the eight E protein amino acid substitutions that distinguish the two strains. The mutants were characterized with respect to WT-specific and vaccine-specific monoclonal antibodies (mAbs) binding to virus plus binding of virus to brain, liver, and lung membrane receptor preparations (MRPs) generated from AG129 mice. This approach shows that amino acids in the YFV E protein domains (ED) I and II contain the WT E protein epitope, which overlap with those that mediate YFV binding to mouse liver. Furthermore, amino acids in EDIII associated with the vaccine epitope overlap with those that facilitate YFV binding mouse brain MRPs. Taken together, these data suggest that the YFV E protein is a key determinant in the phenotype of WT and 17D vaccine strains of YFV.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 University of Texas Medical Branch (UTMB), Department of Pathology, Galveston, USA (GRID:grid.176731.5) (ISNI:0000 0001 1547 9964); UTMB, Sealy Institute for Vaccine Sciences, Galveston, USA (GRID:grid.176731.5) (ISNI:0000 0001 1547 9964)
2 University of Texas Medical Branch (UTMB), Department of Pathology, Galveston, USA (GRID:grid.176731.5) (ISNI:0000 0001 1547 9964)
3 UTMB, Department of Pediatrics, Galveston, USA (GRID:grid.176731.5) (ISNI:0000 0001 1547 9964)
4 Kansas State University, Biosecurity Research Institute, Manhattan, USA (GRID:grid.36567.31) (ISNI:0000 0001 0737 1259); Kansas State University, Department of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Manhattan, USA (GRID:grid.36567.31) (ISNI:0000 0001 0737 1259); Kansas State University, Center on Emerging and Zoonotic Infectious Diseases, College of Veterinary Medicine, Manhattan, USA (GRID:grid.36567.31) (ISNI:0000 0001 0737 1259)
5 UTMB, Sealy Institute for Vaccine Sciences, Galveston, USA (GRID:grid.176731.5) (ISNI:0000 0001 1547 9964); UTMB, Department of Pediatrics, Galveston, USA (GRID:grid.176731.5) (ISNI:0000 0001 1547 9964)